Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Systemic Lupus Erythematosus Treatment Market

Systemic Lupus Erythematosus Treatment Market Share

Report ID: GMI10531
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Systemic Lupus Erythematosus Treatment Market Share

The systemic lupus erythematosus treatment industry is characterized by intense competition, involving both major global companies and smaller to medium-sized companies vying for market dominance. Key to market strategy is the consistent launch of innovative products utilizing various technologies. Major industry leaders play a significant role in driving innovation by making substantial investments in research and development. Moreover, strategic partnerships, acquisitions, and mergers play crucial roles in strengthening market positions and enhancing international presence.

Systemic Lupus Erythematosus Treatment Market Companies

Prominent players operating in the systemic lupus erythematosus treatment industry include:

Anthera Pharmaceuticals, Inc.
Aurinia Pharmaceuticals, Inc.
AstraZeneca
Biogen
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GSK plc.
ImmuPharma PLC
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
Sanofi SA
Sandoz International GmbH

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global systemic lupus erythematosus treatment industry was valued at USD 2.7 billion in 2023 and is anticipated to register 7.6% CAGR between 2024 and 2032 due to increasing prevalence worldwide and rising awareness.

The oral segment in the market is anticipated to witness 7.3% CAGR between 2024-2032 due to their convenience, ease of administration, and efficacy in managing symptoms along with advancements in oral drug formulations.

North America systemic lupus erythematosus treatment market is projected to reach USD 1.9 billion by 2032, driven by robust R&D activities.

Anthera Pharmaceuticals, Inc., Aurinia Pharmaceuticals, Inc., AstraZeneca, Biogen, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GSK plc., and ImmuPharma PLC, among others.